FCF YoY
+950.75%
OCF YoY
+1,680.32%
Capex YoY
+136.37%
FCF Conversion Δ
-77.1 pp
Free cash flow bridge for Alnylam Pharmaceuticals (ALNY) — TTM through Q1 2026 vs TTM through Q1 2025
Δ Free cash flow: $716.72M
FCF bridge breakdown for Alnylam Pharmaceuticals (ALNY) — TTM through Q1 2026 vs TTM through Q1 2025
| Driver | Contribution | % of Δ |
|---|---|---|
| Prior Free Cash Flow | −$75.39M | — |
| Operating Cash Flow | $758.01M | +105.8% |
| Capital Expenditure | −$41.29M | -5.8% |
| Free Cash Flow | $641.34M | — |
- Prior Free Cash Flow−$75.39M
- Operating Cash Flow$758.01M
- Capital Expenditure−$41.29M
- Free Cash Flow$641.34M
Identity check: drivers reconcile to ΔNI within $0.00 ✓
Want to see how cash flow is built up?Cash Flow Waterfall
Frequently asked questions
Data & methodology
Alnylam Pharmaceuticals (ALNY) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Cash Flow
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement